Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer

Inclusion criteria

• Signed the written informed consent form and voluntarily participate in the study.
• Pathohistologically confirmed colon adenocarcinoma with cT3c stage or above.
• Aged 18 to 80 years, regardless of gender.
• The lower edge of the tumor is more than 10 cm from the anus.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Sufficient bone marrow, liver, kidney and coagulation functions assessed by laboratory tests (in accordance with the local laboratory reference range).
• No previous anti-tumor treatment for the current colon cancer (including radiotherapy, chemotherapy, surgery, etc.).
• No pregnancy or lactation for female patients; male patients agree to take effective contraceptive measures during the study.

Exclusion criteria

• Previous anti-tumor treatment for the current colon cancer.
• Previous use of PCSK9 inhibitors or PD-1/PD-L1 inhibitors.
• Active autoimmune diseases or a history of autoimmune diseases.
• Receiving immunosuppressant or systemic glucocorticoid therapy (except for local low-dose glucocorticoid use).
• Active infection requiring systemic anti-infective treatment.
• Severe cardiovascular diseases (e.g., severe hypertension, myocardial infarction, heart failure, etc.).
• Fasting LDL-C <1.0 mmol/L (39 mg/dL), only excluding extremely low levels (suggestive of cachexia/severe hepatic disease)
• Complicated primary tumor (e.g., tumor perforation, intestinal obstruction without relief after intervention).
• Pregnant or lactating women.
• Other conditions that the investigator deems unfit for participation in the study (e.g., poor compliance, severe organ dysfunction, etc.).